CN1953974A - 治疗异常细胞生长的嘧啶衍生物 - Google Patents

治疗异常细胞生长的嘧啶衍生物 Download PDF

Info

Publication number
CN1953974A
CN1953974A CNA2005800155302A CN200580015530A CN1953974A CN 1953974 A CN1953974 A CN 1953974A CN A2005800155302 A CNA2005800155302 A CN A2005800155302A CN 200580015530 A CN200580015530 A CN 200580015530A CN 1953974 A CN1953974 A CN 1953974A
Authority
CN
China
Prior art keywords
amino
methyl
base
alkyl
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800155302A
Other languages
English (en)
Chinese (zh)
Inventor
M·J·卢齐欧
J·C·卡斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Pfizer Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1953974(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1953974A publication Critical patent/CN1953974A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA2005800155302A 2004-05-14 2005-05-02 治疗异常细胞生长的嘧啶衍生物 Pending CN1953974A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14
US60/571,312 2004-05-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011100212904A Division CN102127058A (zh) 2004-05-14 2005-05-02 治疗异常细胞生长的嘧啶衍生物

Publications (1)

Publication Number Publication Date
CN1953974A true CN1953974A (zh) 2007-04-25

Family

ID=34966230

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005800155302A Pending CN1953974A (zh) 2004-05-14 2005-05-02 治疗异常细胞生长的嘧啶衍生物
CN2011100212904A Pending CN102127058A (zh) 2004-05-14 2005-05-02 治疗异常细胞生长的嘧啶衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011100212904A Pending CN102127058A (zh) 2004-05-14 2005-05-02 治疗异常细胞生长的嘧啶衍生物

Country Status (27)

Country Link
EP (1) EP1751143A1 (nl)
JP (1) JP4099212B2 (nl)
KR (1) KR100886990B1 (nl)
CN (2) CN1953974A (nl)
AP (1) AP2241A (nl)
AR (1) AR049097A1 (nl)
AU (2) AU2005243397A1 (nl)
BR (1) BRPI0511138A (nl)
CA (1) CA2566707A1 (nl)
CR (1) CR8749A (nl)
EA (1) EA200601796A1 (nl)
EC (1) ECSP066997A (nl)
GE (1) GEP20104875B (nl)
GT (1) GT200500113A (nl)
IL (1) IL178828A0 (nl)
MA (1) MA28583B1 (nl)
MX (1) MXPA06011890A (nl)
NL (2) NL1029045C2 (nl)
NO (1) NO20064576L (nl)
NZ (1) NZ550448A (nl)
PA (1) PA8632601A1 (nl)
PE (1) PE20060240A1 (nl)
TN (1) TNSN06370A1 (nl)
TW (1) TWI303635B (nl)
UY (1) UY28894A1 (nl)
WO (1) WO2005111023A1 (nl)
ZA (1) ZA200608394B (nl)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448943A (zh) * 2009-05-29 2012-05-09 贝林格尔.英格海姆国际有限公司 用于治疗特征在于过度或异常细胞增殖的疾病的2,4-二氨基嘧啶
CN103951658A (zh) * 2007-04-18 2014-07-30 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
CN109608444A (zh) * 2018-11-27 2019-04-12 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548A (zh) * 2020-06-11 2020-10-02 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途
WO2024140671A1 (zh) * 2022-12-29 2024-07-04 南京昕瑞再生医药科技有限公司 一种稠三环类衍生物、包含其的药物组合物及其用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566531A1 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
KR101060051B1 (ko) * 2005-12-21 2011-08-29 화이자 프로덕츠 인크. 비정상적인 세포 성장을 치료하기 위한 피리미딘 유도체
EP2183225A1 (en) * 2007-07-17 2010-05-12 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
EP2231620A1 (en) * 2007-12-03 2010-09-29 Boehringer Ingelheim International GmbH Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
EA029131B1 (ru) * 2008-05-21 2018-02-28 Ариад Фармасьютикалз, Инк. Фосфорсодержащие производные в качестве ингибиторов киназы
JP5539518B2 (ja) 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 2−アミノ−5−トリフルオロメチルピリミジン誘導体の位置選択的調製
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2014174745A1 (ja) * 2013-04-26 2014-10-30 国立大学法人京都大学 Eg5阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
PT1625121E (pt) * 2002-12-20 2010-03-11 Pfizer Prod Inc Derivados de piridina para o tratamento de crescimento celular anormal
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103951658A (zh) * 2007-04-18 2014-07-30 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
CN103951658B (zh) * 2007-04-18 2017-10-13 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
CN102448943A (zh) * 2009-05-29 2012-05-09 贝林格尔.英格海姆国际有限公司 用于治疗特征在于过度或异常细胞增殖的疾病的2,4-二氨基嘧啶
CN109608444A (zh) * 2018-11-27 2019-04-12 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548A (zh) * 2020-06-11 2020-10-02 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途
WO2024140671A1 (zh) * 2022-12-29 2024-07-04 南京昕瑞再生医药科技有限公司 一种稠三环类衍生物、包含其的药物组合物及其用途

Also Published As

Publication number Publication date
UY28894A1 (es) 2005-12-30
TNSN06370A1 (fr) 2008-02-22
CN102127058A (zh) 2011-07-20
TW200539871A (en) 2005-12-16
TWI303635B (en) 2008-12-01
GT200500113A (es) 2006-01-10
PA8632601A1 (es) 2006-06-02
AR049097A1 (es) 2006-06-28
WO2005111023A1 (en) 2005-11-24
KR20070012477A (ko) 2007-01-25
MXPA06011890A (es) 2006-12-14
AU2009238255A1 (en) 2009-12-03
AU2005243397A1 (en) 2005-11-24
ZA200608394B (en) 2008-05-28
IL178828A0 (en) 2007-03-08
GEP20104875B (en) 2010-01-11
NL1029045A1 (nl) 2005-11-15
EP1751143A1 (en) 2007-02-14
ECSP066997A (es) 2007-02-28
BRPI0511138A (pt) 2007-11-27
PE20060240A1 (es) 2006-04-01
AP2241A (en) 2011-06-01
MA28583B1 (fr) 2007-05-02
NL1031845A1 (nl) 2006-07-31
NO20064576L (no) 2006-11-07
CA2566707A1 (en) 2005-11-24
JP2007537234A (ja) 2007-12-20
AP2006003790A0 (en) 2006-10-31
KR100886990B1 (ko) 2009-03-04
NZ550448A (en) 2010-11-26
EA200601796A1 (ru) 2007-04-27
JP4099212B2 (ja) 2008-06-11
CR8749A (es) 2006-12-05
NL1029045C2 (nl) 2006-06-02
NL1031845C2 (nl) 2006-11-23

Similar Documents

Publication Publication Date Title
CN1953974A (zh) 治疗异常细胞生长的嘧啶衍生物
CN101346380B (zh) 用于治疗异常细胞生长的嘧啶衍生物
US7109337B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
JP5989664B2 (ja) 治療用の化合物および組成物
EP1625121B1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
US7145008B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW202115024A (zh) 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
JP2007537235A (ja) 異常細胞増殖の治療用ピリミジン誘導体
CN101678215A (zh) 用于治疗异常细胞生长的磺酰胺衍生物
WO2021041360A1 (en) Triazolopyrimidines as a2a / a2b inhibitors
US20060205945A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1105203

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070425

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1105203

Country of ref document: HK